| 7.81 0.01 (0.13%) | 05-04 12:04 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.57 | 1-year : | 11.18 |
| Resists | First : | 8.19 | Second : | 9.57 |
| Pivot price | 7.75 |
|||
| Supports | First : | 7.31 | Second : | 6.76 |
| MAs | MA(5) : | 7.67 |
MA(20) : | 7.63 |
| MA(100) : | 7.67 |
MA(250) : | 7.88 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 55 |
D(3) : | 47.4 |
| RSI | RSI(14): 55.7 |
|||
| 52-week | High : | 11.77 | Low : | 6.57 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ GYRE ] has closed below upper band by 38.2%. Bollinger Bands are 30.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.9 - 7.93 | 7.93 - 7.95 |
| Low: | 7.37 - 7.41 | 7.41 - 7.44 |
| Close: | 7.74 - 7.8 | 7.8 - 7.85 |
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Mon, 04 May 2026
Gyre Therapeutics closes $300M Cullgen acquisition - Investing.com
Mon, 04 May 2026
Gyre Therapeutics Completes Cullgen Acquisition and Leadership Transition - TipRanks
Mon, 04 May 2026
Gyre Therapeutics (GYRE) closes $300M Cullgen deal, adds degrader pipeline - Stock Titan
Mon, 04 May 2026
A $300M biotech merger gives Gyre a China drug business and new CEO - Stock Titan
Mon, 04 May 2026
Gyre Therapeutics Completes Acquisition Of Cullgen To Create U.S.- And China-Based Fully Integrated Biopharmaceutical Company - TradingView
Sat, 02 May 2026
GYRE Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 81.5 (%) |
| Held by Institutions | 3.4 (%) |
| Shares Short | 1,580 (K) |
| Shares Short P.Month | 1,380 (K) |
| EPS | 0.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.15 |
| Profit Margin | 4.3 % |
| Operating Margin | 0.3 % |
| Return on Assets (ttm) | 4.9 % |
| Return on Equity (ttm) | 8.2 % |
| Qtrly Rev. Growth | 33.4 % |
| Gross Profit (p.s.) | 1.14 |
| Sales Per Share | 1.2 |
| EBITDA (p.s.) | 0.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | 392.5 |
| PEG Ratio | 0 |
| Price to Book value | 6.76 |
| Price to Sales | 6.53 |
| Price to Cash Flow | 753.83 |
| Dividend | 3.59 |
| Forward Dividend | 0 |
| Dividend Yield | 45.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|